Key Takeaways from the 2022 Healthcare Insurance Symposium
Articles & stories

Key Takeaways from the 2022 Healthcare Insurance Symposium

The enhanced HIX subsidies implemented last May could be extended, but closing the coverage gap in Medicaid is not expected to pass. Our expert believes that further delays in clinical lab PAMA cuts could be extended for another year as part of an Omnibus 2023 Appropriations bill that could pass in 4Q22 or 1Q23.

During the Medicare Market Session, supplemental benefits (groceries, meals) remained a focus, and the favorable rate update is expected to allow plans to become even more creative with these in 2023. For plan year 2024, a step back for some M.A. plans in their Star ratings is possible as pandemic-related adjustments end.

Our presenter believes brand name recognition may help some providers grow but sees the growth journey as more of a marathon than a sprint. Our presenter sees tech-enabled MCOs eventually drawing some interest from larger MCOs for their proprietary technology rather than their membership.

Our expert suggested during the Medicaid Market session that a mid-single-digit percentage of those currently enrolled on Medicaid have secured other coverage, as the pandemic has dragged on and might be double-counted. He also believes that 5-15% of those on the Medicaid rolls could ultimately be cut from the existing rolls as redeterminations start. A few states could see as much as one-third of members declared ineligible. He agreed that those members rolling off are likely to be somewhat healthier than those who remain covered by Medicaid; however, he also believes states may wait to see how the economic backdrop unfolds before adjusting rates.

Regarding rebate guarantees, our presenter believes most PBM contracts contain language that would allow for adjustments if a biosimilar/generic launches and reduces rebate dollars. Our presenter also discussed the 340B program and its difficulties for a PBM and health plan. He argued that the current dispute between drug manufacturers and health systems/contract pharmacies would not likely be solved via negotiation but rather by regulators and the courts.

@A. J. Rice

Related Articles

  1. Therapeutic Journeys in Diabetes: A focus on GLP-1 drugs

    Therapeutic Journeys in Diabetes: A focus on GLP-1 drugs
    The proportion of patients starting GLP or GIP-GLP treatment without prior diabetes treatment has risen substantially in recent quarters. Our analysis accords well with historical Novo Nordisk's Wegovy in '21 and Eli Lilly's Mounjaro in '22 commentary and brings the data forward to look at 1Q 2023.

  2. No changes in our European utility convictions

    No changes in our European utility convictions
    The European utility sector has seen little differentiation in performance across the past three months, with a 9% increase in absolute terms and a 5% outperformance versus the MSCI Europe. Energy prices have fallen, but windfall taxes and price caps introduced in 2022 could limit near-term negative earnings per share (EPS) momentum. But the sector has already de-rated to reflect this.

  3. What could Europe’s green subsidy plan look like?

    What could Europe’s green subsidy plan look like?
    With the European Green Deal announced in 2019, Europe was the first to declare its ambition to be a climate-neutral continent. COVID-19 and the complexities of European green subsidies meant that considerable funds are still to be deployed. In the meantime, the US Inflation Reduction Act (announced in July 2022) has received significant attention owing to the simplicity of the mechanism and the potential for a more favourable policy to attract investment into the country. This policy move has prompted the European Commission to respond with the proposed Green Deal Industrial Plan (“GDIP”) to mobilise various forms of state aid for the green transition.